CT26-hSIGLEC15
Strain Information
Validation Data
Figure 1. Expression of human SIGLEC15 on CT26-hSIGLEC15 cells was confirmed by flow cytometry.
CT26-hSIGLEC15 cells and wild type CT26 cells were stained with species-specific anti-SIGLEC15 antibody. FACS analysis shows that human SIGLEC15 expression on CT26-hSIGLEC15 cells was detectable. Human SIGLEC15 expression of 18# and 28# clones were 52.65% and 93.15%.
Figure 2. In vivo tumor growth curves in humanized CT26-hSIGLEC15 syngeneic model.
BALB/c mice were subcutaneously injected CT26-hSIGLEC15 cells. Tumor growth was monitored by measuring tumor size from day 14 after subcutaneous implantation.
Figure 3. FACS analysis of SIGLEC15 expression on tumor cells derived from humanized CT26-hSIGLEC15 syngeneic model with species-specific anti-SIGLEC15 antibodies.
FACS analysis shows that human SIGLEC15 expression in human SIGLEC15 knock-in tumor were 48.61% (18# clone) and 60.48% (28# clone).
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
